Avoid alcohol and tobacco and spicy,cold, greasy food during taking this product. Zhong Y., Zhou J., Liang N., Liu B., Lu R., He Y., Liang C., Wu J., Zhou Y., Hu M., Zhou J. (2020). Efficacy and Safety of Lianhuaqingwen for Mild or Moderate Coronavirus Disease 2019. Pharmacol. 13 (08), 676681. Preliminary Study on the Inhibitory Effect of Lianhua Qingwen Capsule on virusMaster Degree. Anal. Theoretical research basis and clinical efficacy of Lianhua Qingwen in treating Novel Coronavious pneumonica. A study by Lei (2020) on childhood influenza treatment revealed no statistical difference of adverse effects between LHQW group and conventional drug group (p = 0.751), inconsistent with our meta-analysis. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. [9], During the COVID-19 pandemic, the government of the People's Republic of China (PRC) approved the use of Lianhua Qingwen for mild to moderate COVID-19 cases in January 2020, and promotes the use of the medicine abroad. However, no statistical difference was detected with regard to rash (RR = 0.60, 95% CI = 0.211.67) and dizziness (RR = 1.79, 95% CI = 0.339.74). Electronic retrieval was performed using following databases, which were searched from outset to February 18, 2021: Embase, PubMed, the Cochrane Library, CNKI (a Chinese database), VIP (a Chinese database), and Wanfang (a Chinese database). It is urgent to develop effective drugs to contain and treat COVID-19. Additionally, LHQW group also had shorter time to recovery of fever, fatigue and coughing, and higher improvement rate in chest computed tomographic manifestations and clinical cure [43]. Med. the Need for Accurate Scientific Nomenclature for Plants. Compared with oseltamivir, LHQW achieved a similar therapeutic effectiveness with reduction of the duration of illness and duration of influenza A virus H1N1 shedding [36]. However, no consensus has been reached on the security of LHQW to date. ChemRxiv. It may benefit the treatment of COVID-19 by the signaling pathways such as advanced glycation end products (AGE)-receptor of AGE (RAGE), TNF, sarcoma-associated herpesvirus infection, IL-17 and human cytomegalovirus infection [41]. Four studies reported body as a whole-general disorders as an adverse event. There was no statistically significant difference in the incidence of hepatobiliary system damage between the LHQW group and the conventional drug group (RR = 0.86, 95% CI = 0.581.28, p = 0.461). Lianhua Qingwen capsules have been proven to speed up symptoms recovery but no effect in preventing infections from worsening. The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author. 37 studies reported adverse reactions of skin and its appendage damage. CFDA has recently approved adding a new indication for LHQW in mild and common COVID-19 patients, but whether it would bring benefits for the severe cases is unclear. Pharmacol. It blocked the early stages (02h) of virus infection, and reduced virus-induced nuclear factor-kappa B (NF-B) activation and the gene expression of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-, interferon-inducible protein (IP)-10, and monocyte chemoattractant protein (MCP)-1 [24]. Vahl. We hope this review will not only present comprehensive evidence for LHQW use in COVID-19 therapy, but also fuel antiviral researches and put forward promising insights for further antiviral drug development. Measuring Inconsistency in Meta-Analyses. A Trial of Lopinavir-Ritonavir in Covid-19. Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. Percentage of risk of bias for all qualified studies. A systematic review on the efficacy of Traditional Chinese Medicine on influenza. Clinically, Lianhua Qingwen Capsule can be used in the treatment of cold, flu-induced bronchitis, pneumonia, COPD, interstitial pneumonia and other lung inflammation. No adverse treatment-related effects were reported in all the included publications (from 2009 to 2011). However, the efficacy and safety of which shall be confirmed by more high-quality clinical trials. Jie Chen, Qin Chen and Hua-Qian Jin analyzed literatures. (1990). Finally, our data showed that LHQW reduces the incidence of a number of adverse reactions compared with conventional drugs. Sci.). Drafting of the manuscript was done by CH and BH. Pharmacol. Besides, in view of the definite effects of LHQW in preventing severe viral infections such as SARS and COVID-19 [17,44,45,49,52,53], LHQW may represent a considerable and effective strategy against unknown viral epidemics. 367 (6485), 14121413. Inhibitorv Effect of Lianhua Oingwen Water Extract on Methicillin-Resistant staphylococcus Aureus Biofilm In Vitro. This work was supported by the National Natural Science Foundation of China (No. HHS Vulnerability Disclosure, Help Literature searching and extraction of data were done by CH, BH, FG, and ML. Seven of the studies showed that adverse reactions improved or healed spontaneously without any treatment, five reported that adverse reactions healed spontaneously after discontinuation of medication, eight showed that adverse reactions improved or healed with medication after meals and ten showed that adverse reactions improved or recovered after symptomatic treatment, while in the remaining eight studies, adverse reactions were not disposed or treated. Other related clinical studies also revealed that LHQW significantly improved the symptoms in COVID-19 patients and reduced the duration of fever, fatigue and cough and so forth, which provide preliminary research evidence for clinical treatment of COVID-19 [45,46]. Bras (1992). The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. The outcome measures included the alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza. The serious attack of Coronavirus Disease 2019 (COVID-19), infected by Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (SARS-CoV-2), has quickly spread around the globe [[1], [2], [3]]. J. Nanjing Univ. Alternat Med. 26 (11), 812. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Available at: http://www.plantsoftheworldonline.org (Accessed December 18, 2021). Methods and analysis : We systematically searched the Medline (OVID), Embase, the Cochrane Library, and 4 Chinese databases from inception to July 2020 to include the RCTs that evaluated the . Ling X.Y., Tao J.L., Sun X., Yuan B. Lv R.B., Wang W.J., Li X. (2021). Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. Wu et al. 48 (3), 737762. The following aspects were assessed for each study: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. Rev. Furthermore, we also found that LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group. Beijing: China Medical Science Press. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). As a library, NLM provides access to scientific literature. The China National Medical Products Administration agency has officially approved LHQW for the treatment of mild or ordinary COVID-19 pneumonia (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). ex DC. (Lianqiao), Lonicera japonica Thunb. Clin. Pharmacol. Subgroup, sensitivity and meta-regression analyses were conducted to determine the potential sources of heterogeneity. No statistical difference was detected for sleepy. J. Eval. Current evidence shows that Lianhua Qingwen capsule is more effective and safer than Oseltamivir, Ribavirin and Ankahuangmin capsules. N. Engl. Chin. Therefore, we conducted a systematic review of the . The site is secure. Few reports of adverse reactions in the course of treating COVID-19 pneumonia with LHQW are available. Retrospective Clinical Analysis on Treatment of Novel Coronavirus-Infected Pneumonia with Traditional Chinese Medicine Lianhua Qingwen. Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . Conclusion: The current study provides potential a reference for the security of LHQW. Business China. doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. In conclusion, this review has summarized the benefits of LHQW for treating virus infection, especially its anti-SARS-CoV-2 role as an alternative candidate and complementary strategy. In response to the severe SARS-CoV-2 attack, TCM has gained high usage in recent several months especially in China [47]. The Cochrane Collaboration risk of bias tool comprising seven items was applied to assess the risk of bias of each eligible study (Higgins et al., 2011). Secondly, separate evaluations were further performed for different diseases and types of adverse reactions. Alternat Med. A Working List of All Plant Species. There was no statistically significant difference in the incidence of adverse reactions during treatment of common pneumonia between the LHQW group and the conventional drug group (RR = 0.99, 95% CI = 0.791.24, p = 0.927). These above ingredients are decocted, distilled, filtered, refrigerated, mixed well with powdered sugar, dextrin or starch, dried and finally made into LHQW (Chinese Pharmacopoeia, 2020). Vahl (Lianqiao); Lonicera japonica Thunb. Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. Liu-Cheng Li was responsible for drafting the manuscript. Firstly, to our knowledge, this meta-analysis provides the most comprehensive evaluation of the clinical safety of LHQW. In addition, LHQW had antagonist effects on the pulmonary oxidative lesions that induced by fine particulates PM2.5 in rats [34]. No use, distribution or reproduction is permitted which does not comply with these terms. From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment. In a lipopolysaccharide (LPS)-induced acute lung injury animal model, LHQW could efficiently decrease the chemotaxis of monocytes toward the pulmonary infection foci, and thus blocked the disease development by down-regulating MCP-1 expression [33]. We would like to express our appreciation to all authors of eligible studies which were included in the current meta-analysis. All authors approved the final version of this manuscript. The post-marketing monitoring data incorporated information on the following gastrointestinal adverse reactions: nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth; as well as skin rash, itching, dizziness (Yiling Pharmaceutical, 2021). 46 (5), 395400. Lianhua-qingwen Displays Antiviral and Anti-inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. Literature analysis of Chinese patent medicine treatment in the observation period of Clinical Management of Corona Virus Disease 2019 (trial 6th edition). Asia-Pacific Traditional Med. Avoid prolonged use. The results remained statistically robust after different number supplement of potential studies (for hepatobiliary system damage: RR = 0.90, 95% CI = 0.60 to 1.34; for psychiatric disorders: RR = 1.00, 95% CI = 0.20 to 4.91; for gastrointestinal system damage: RR = 0.86, 95% CI = 0.76 to 0.98; for body as a whole-general disorders: RR = 0.73, 95% CI = 0.212.56). aimed to assess the efficacy and safety of LH combined with usual treatment vs usual treatment alone in treating mild or moderate COVID-19 by a meta-analysis of randomized controlled trials (RCTs).
Kyle Chandler Ron Livingston Mark Duplass,
Kent County, Maryland Property Search,
Journal Entry For Advance Payment To Vendor,
Why Isn T Matt Damon Credited In Thor: Ragnarok,
Articles L